Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis

被引:25
|
作者
Kantarci, O. H. [1 ]
Pirko, I. [1 ]
Rodriguez, M. [2 ]
机构
[1] Mayo Clin, Dept Neurol, Rochester, MN USA
[2] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
PLACEBO-CONTROLLED TRIAL; NEURITIS TREATMENT TRIAL; CENTRAL-NERVOUS-SYSTEM; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; INFLAMMATORY-DEMYELINATING DISEASE; ACUTE OPTIC NEURITIS; NATURAL-HISTORY; FOLLOW-UP; DOUBLE-BLIND; PLASMA-EXCHANGE;
D O I
10.1038/clpt.2013.196
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We provide a focused review of novel immunomodulatory approaches for the treatment of multiple sclerosis, the most common acquired inflammatory demyelinating disease of humans. The requirement for such a review was stimulated by the emerging application of novel,oral medications and the need for the practicing physician to place these within the treatment paradigm. We provide a conceptual diagram of our current view of the pathogenesis of demyelination and remyelination in this disorder. In addition, we include a working template on how to use a tier 1 and tier 2 approach to medications as the disease worsens in the individual. We emphasize the approach of treatment based on "individualized medicine," tailored to the specific needs of each patient. In the future, we envision new drugs to enhance remyelination and protect neurons and axons from death in order to promote central nervous system regeneration and repair.
引用
收藏
页码:32 / 44
页数:13
相关论文
共 50 条
  • [31] IMMUNOMODULATORY PROPERTIES OF LIF AND OSM IN MULTIPLE SCLEROSIS
    Janssens, K.
    Slaets, H.
    Vanwijmeersch, B.
    Stinissen, P.
    Hendriks, J.
    Hellings, N.
    GLIA, 2013, 61 : S181 - S182
  • [32] Immunomodulatory medicines for multiple sclerosis: Progress and prospects
    Palmer, Alan M.
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 664 - 673
  • [33] Immunomodulatory effects of Vitamin D in multiple sclerosis
    Correale, Jorge
    Celica Ysrraelit, Mara
    Ines Gaitan, Maria
    BRAIN, 2009, 132 : 1146 - 1160
  • [34] IMMUNOMODULATORY AND THERAPEUTIC PROPERTIES OF LIF IN MULTIPLE SCLEROSIS
    Janssens, K.
    Slaets, H.
    Baekelandt, V
    Van den Haute, C.
    Vanwijmeersch, B.
    Eijnde, Op't B.
    Stinissen, P.
    Hendriks, J.
    Hellings, N.
    GLIA, 2011, 59 : S140 - S140
  • [35] Comparison of immunomodulatory treatments for multiple sclerosis - Reply
    Haas, J
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (11) : 916 - 916
  • [36] Cladribine: An Investigational immunomodulatory agent for multiple sclerosis
    Brousil, Julie A.
    Roberts, Russel J.
    Schlein, Amanda L.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (10) : 1814 - 1821
  • [37] The effect of immunomodulatory treatment on multiple sclerosis fatigue
    Metz, LM
    Patten, SB
    Archibald, CJ
    Bakker, JI
    Harris, CJ
    Patry, DG
    Bell, RB
    Yeung, M
    Murphy, WF
    Stoian, CA
    Billesberger, K
    Tillotson, L
    Peters, S
    McGowan, D
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (07): : 1045 - 1047
  • [38] Pregnancy and immunomodulatory therapy in multiple sclerosis patients
    Hoffmann, L. A.
    Kuempfel, T.
    Heer, I.
    Hohlfeld, R.
    NERVENARZT, 2006, 77 (06): : 663 - +
  • [39] Identification of novel protein candidates involved in immunomodulatory processes in therapy and pathomechanism of multiple sclerosis
    Knop, M. J.
    Nischwitz, S.
    Faber, H.
    Uhr, M.
    Turck, C. W.
    Weber, F.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 333 - 333
  • [40] Immunomodulatory therapy in the early phases of multiple sclerosis
    Chan, A
    Rieckmann, P
    Gold, R
    NERVENHEILKUNDE, 2001, 20 (04) : 237 - 243